Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07403721 · ClinicalTrials.gov registry record · Phase 1
AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors
A Phase 1 study of Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR), sponsored by Amgen.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 464
- Enrollment target
- 2
- Study locations
NCT07403721: Recruiting Phase 1 study of Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR), sponsored by Amgen.
NCT07403721 is a Phase 1 study of Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR) that is actively recruiting participants, run by Amgen. The registered enrollment target is 464 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (673% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07403721, a Phase 1 study of Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR), is actively recruiting participants, sponsored by Amgen.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 464 participants
- Enrollment target
- 2
- Study locations
Study Summary
The primary objectives of this trial are to evaluate the safety profile of AMG 436 and to determine the maximum tolerated dose (MTD) and/or the recommended dose for AMG 436 as monotherapy and in combination with other anti-cancer therapies in participants with MSI-H/dMMR solid tumors.
Conditions Studied
Interventions
- DRUG AMG 436
Study Locations (2)
Texas
- Next Oncology - Dallas - Irving
Aichi-ken
- Aichi Cancer Center - Nagoya
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 464 participants |
| Start Date | 2026-03-23 |
| Est. Completion | 2028-06-28 |
| Phase | Phase 1 |
What NCT07403721 shows while recruiting
NCT07403721 is an interventional study that assigns participants to a tested intervention. The registered 464 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (673% higher).
The record links to 1 condition, with Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR) appearing as the primary indexed condition, and to 1 intervention - of which AMG 436 is the first listed.
NCT07403721 reports a single indexed study location in Texas, Aichi-ken.
Frequently Asked Questions
What is clinical trial NCT07403721 about?
NCT07403721 is a clinical study titled "AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors". The primary objectives of this trial are to evaluate the safety profile of AMG 436 and to determine the maximum tolerated dose (MTD) and/or the recommended dose for AMG 436 as monotherapy and in combination with other anti-cancer therapies in participants with MSI-H/dMMR solid tumors.
What is the current status of trial NCT07403721?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 464 participants. The study started on 2026-03-23. Estimated completion is 2028-06-28.
What conditions does trial NCT07403721 study?
This clinical trial studies the following conditions: Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR).
What interventions are being tested in trial NCT07403721?
The interventions under investigation include: AMG 436 (DRUG).
Who is sponsoring clinical trial NCT07403721?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07403721 being conducted?
This trial has 2 study locations across Texas, Aichi-ken. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07403721's enrollment target sits among peer trials
464 52nd of 2000 higher than 1,948 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04787744 · 464 participants · Phase 2
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
- NCT04855656 · 464 participants · Phase 1
Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors
- NCT06283927 · 464 participants
The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)
- NCT06444295 · 464 participants · NA
Testing the Impact of Thrive App Versions on Alcohol Use and Posttraumatic Stress After Recent Sexual Assault
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI